Volume 6 Issue 1, January 15, 2019
The healthcare industry continues to be an evolving and complex industry, and federal and state laws and regulations that govern the industry and business transactions are equally changing and complex.
Intriguingly, given the volatile healthcare industry, owners of a healthcare business/practice rarely seek to understand the value of their company unless they consider it a necessity, such as settling a shareholder/partner dispute, getting a divorce, or obtaining a bank loan. The problem with this way of thinking is that most owners of a healthcare business miss the opportunity to better understand the value of their company, how to strategically increase its value over time, and how to integrate a company/practice value with their personal financial planning.
Here are several key reasons why getting a valuation of your healthcare company might be the most important thing you do this year:
Learning What Your Company is (and Could be) Worth – Many owners wait until a life-changing event has occurred, or is about occur, before valuing their healthcare company, often when it’s too late to make changes that increase value. For example, we recently performed a valuation of a behavioral healthcare company where the majority owner is in his mid-60’s and wished to sell the company. The owner was surprised to learn that the value of the company was about half the value he had hoped it would be. Had we valued the company three to five years earlier he would have had an independent, market-based expectation of the company’s future value, and he could have taken steps to increase its value before selling.
Multi-Owner Healthcare Companies Getting on the Same Page – It’s highly likely that each partial owner of a healthcare company has a different expectation of value than their partners. Having very diverse expectations of company value that are not openly discussed and considered, can lead owners to make poor decisions. For example, a durable medical equipment (DME) client with several owners had one owner who planned to exit the company in a couple of years. The partial owner presumed the remaining owners would buy his ownership interest for a price he had contrived on his own. After we completed an independent valuation, the owners were somewhat surprised by our value determination, especially the retiring partner whose price significantly exceeded reasonable value parameters. The partial owner stated that, due to the valuation results, he would delay his retirement and instead work hard for the next few years to increase company value.
Learning the Key Value Drivers of Your Company Based on a Buyer’s Perspective – Most owners of healthcare companies focus on top-line, bottom-line outcomes as key value drivers. While revenue and profit growth favorably impact value, there are many other value drivers. For example, we recently valued a sole practitioner dental practice, where we discovered that the landlord of the building was unwilling to renew the lease on a long-term basis, all business decisions were made solely by the dentist, the employees had little autonomy, the practice used older technologies, and a significant amount of revenues were from contracted dental plans. Needless to say, the dentist was not pleased by the valuation results, but he did learn what he would have to do to improve value. The earlier the valuation, the more opportunity there is to enhance value over time.
Understanding Your Options – Many owners of healthcare companies report being approached by one or more potential buyers out of the blue, including very reputable investors who have discovered a particular niche. Knowing the value of your healthcare company, and perhaps having an idea of the future potential value, puts you in a position of negotiation strength. For example, soon after completing a valuation of their OB/GYN practice, our client was approached by a local hospital about selling the practice. The owners were well-prepared to evaluate and negotiate the hospital’s offer after having recently completed a valuation. Obtaining a market-based valuation of your company is a very cost-effective way to understand value and plan for the future in today’s dynamic healthcare marketplace. Not only will you know about your company’s value, but you will also have a keener sense of what you need to do to build value over time for your employees, as well as your family.
David is a seasoned commercial and corporate finance professional with over 30 years’ experience. As part of the VERTESS team, he provides clients with valuation, financial analysis, and consulting support. He has completed over 150 business valuations. Most of the valuation work he does at VERTESS is for healthcare companies such as behavioral healthcare, home healthcare, hospice care, substance use disorder treatment providers, physical therapy, physician practices, durable medical equipment companies, outpatient surgical centers, dental offices, and home sleep testing providers.
David holds certifications as a Certified Valuation Analyst (CVA), issued by the National Association of Certified Valuators and Analysts, Certified Value Growth Advisor (CVGA), issued by Corporate Value Metrics, Certified Merger & Acquisition Advisor (CM&AA), issued by the Alliance of Merger & Acquisition Advisors, and Certified Business Exit Consultant (CBEC), issued by Pinnacle Equity Solutions. Moreover, the topic of his doctoral dissertation was business valuation.
David earned a Doctorate in Business Administration from Walden University with a specialization in Corporate Finance (4.0 GPA), an MBA from Keller Graduate School of Management, and a BS in Economics from Northern Illinois University. He is a member of the Golden Key International Honor Society and Delta Mu Delta Honor Society.
Before joining Vertess, David spent approximately 20 years in commercial finance, having worked in senior-level management positions at two Fortune 500 companies. During his commercial finance career, he analyzed the financial condition of thousands of companies and had successfully sold over $2 billion in corporate debt to institutional buyers.
He is a former adjunct professor with 15 years' experience teaching corporate finance, securities analysis, business economics, and business planning to MBA candidates at two nationally recognized universities.